Published in Nat Rev Drug Discov on August 01, 2010
Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. Cancer Metastasis Rev (2013) 2.46
Synthesis and profiling of a diverse collection of azetidine-based scaffolds for the development of CNS-focused lead-like libraries. J Org Chem (2012) 1.24
Local partition coefficients govern solute permeability of cholesterol-containing membranes. Biophys J (2013) 1.04
Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity. Proc Natl Acad Sci U S A (2012) 1.03
Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance. Chem Rev (2014) 1.00
The effect of nanoparticle uptake on cellular behavior: disrupting or enabling functions? Nanotechnol Sci Appl (2012) 1.00
Evidence for annexin A6-dependent plasma membrane remodelling of lipid domains. Br J Pharmacol (2015) 0.90
Layered double hydroxide nanocomposite for drug delivery systems; bio-distribution, toxicity and drug activity enhancement. Chem Cent J (2014) 0.89
Nanoparticle mediated non-covalent drug delivery. Adv Drug Deliv Rev (2012) 0.89
Nuclear export mediated regulation of microRNAs: potential target for drug intervention. Curr Drug Targets (2013) 0.88
Ligand and structure-based classification models for prediction of P-glycoprotein inhibitors. J Chem Inf Model (2014) 0.87
Reduced ABCB1 Expression and Activity in the Presence of Acrylic Copolymers. Adv Pharm Bull (2014) 0.86
The fraction dose absorbed, in humans, and high jejunal human permeability relationship. Mol Pharm (2012) 0.86
What can we learn from the evolution of protein-ligand interactions to aid the design of new therapeutics? PLoS One (2012) 0.86
Global expression of molecular transporters in the human vaginal tract: implications for HIV chemoprophylaxis. PLoS One (2013) 0.85
Novel preclinical models of topical PrEP pharmacodynamics provide rationale for combination of drugs with complementary properties. Retrovirology (2013) 0.84
Intracellular distribution of nontargeted quantum dots after natural uptake and microinjection. Int J Nanomedicine (2013) 0.83
Function and expression of the proton-coupled amino acid transporter PAT1 along the rat gastrointestinal tract: implications for intestinal absorption of gaboxadol. Br J Pharmacol (2012) 0.83
Tumor P-Glycoprotein Correlates with Efficacy of PF-3758309 in in vitro and in vivo Models of Colorectal Cancer. Front Pharmacol (2013) 0.81
Microengineered cell and tissue systems for drug screening and toxicology applications: Evolution of in-vitro liver technologies. Technology (Singap World Sci) (2015) 0.81
Transport inhibition of digoxin using several common P-gp expressing cell lines is not necessarily reporting only on inhibitor binding to P-gp. PLoS One (2013) 0.81
A primary fish gill cell culture model to assess pharmaceutical uptake and efflux: evidence for passive and facilitated transport. Aquat Toxicol (2014) 0.81
Retracted Immunohistochemical and functional characterization of peptide, organic cation, neutral and basic amino acid, and monocarboxylate drug transporters in human ocular tissues. Drug Metab Dispos (2012) 0.80
Understanding transport through pharmacological barriers--are we there yet? Nat Rev Drug Discov (2010) 0.80
pH Dependent but not P-gp Dependent Bidirectional Transport Study of S-propranolol: The Importance of Passive Diffusion. Pharm Res (2015) 0.79
Facilitated uptake of a bioactive metabolite of maritime pine bark extract (pycnogenol) into human erythrocytes. PLoS One (2013) 0.79
Quantitative analysis of molecular transport across liposomal bilayer by J-mediated 13C Overhauser dynamic nuclear polarization. Anal Chem (2012) 0.79
Differential Mechanisms of Tenofovir and Tenofovir Disoproxil Fumarate Cellular Transport and Implications for Topical Preexposure Prophylaxis. Antimicrob Agents Chemother (2015) 0.78
How do antimalarial drugs reach their intracellular targets? Front Pharmacol (2015) 0.78
Target-independent prediction of drug synergies using only drug lipophilicity. J Chem Inf Model (2014) 0.78
Lysosomal pH-inducible supramolecular dissociation of polyrotaxanes possessing acid-labile N-triphenylmethyl end groups and their therapeutic potential for Niemann-Pick type C disease. Sci Technol Adv Mater (2016) 0.78
A BOILED-Egg To Predict Gastrointestinal Absorption and Brain Penetration of Small Molecules. ChemMedChem (2016) 0.78
Intestinal organoids for assessing nutrient transport, sensing and incretin secretion. Sci Rep (2015) 0.78
Defined lipid analogues induce transient channels to facilitate drug-membrane traversal and circumvent cancer therapy resistance. Sci Rep (2013) 0.77
A new in situ brain perfusion flow correction method for lipophilic drugs based on the pH-dependent Crone-Renkin equation. Pharm Res (2010) 0.77
Synthesis and characterization of layered double hydroxides and their potential as nonviral gene delivery vehicles. ChemistryOpen (2014) 0.77
Structural perturbation of a dipalmitoylphosphatidylcholine (DPPC) bilayer by warfarin and its bolaamphiphilic analogue: A molecular dynamics study. J Colloid Interface Sci (2016) 0.76
Dose-dependent targeted suppression of P-glycoprotein expression and function in Caco-2 cells. Mol Pharm (2013) 0.76
Getting across the cell membrane: an overview for small molecules, peptides, and proteins. Methods Mol Biol (2015) 0.76
Drug Transporter Expression and Activity in Human Hepatoma HuH-7 Cells. Pharmaceutics (2016) 0.75
Assessing the reliability of uptake and elimination kinetics modelling approaches for estimating bioconcentration factors in the freshwater invertebrate, Gammarus pulex. Sci Total Environ (2016) 0.75
The Flip-Flop Diffusion Mechanism across Lipids in a Hybrid Bilayer Membrane. Biophys J (2016) 0.75
Structural features determining the intestinal epithelial permeability and efflux of novel HIV-1 protease inhibitors. J Pharm Sci (2011) 0.75
Significance of lipid composition in a blood-brain barrier-mimetic PAMPA assay. J Biomol Screen (2013) 0.75
Exploration of the protection of riboflavin laurate on oral mucositis induced by chemotherapy or radiotherapy at the cellular level: what is the leading contributor? Int J Mol Sci (2013) 0.75
Impact of Sex on the Pharmacokinetics and Pharmacodynamics of 1% Tenofovir Gel. Clin Infect Dis (2015) 0.75
2D- and 3D-QSAR studies of a series of benzopyranes and benzopyrano[3,4b][1,4]-oxazines as inhibitors of the multidrug transporter P-glycoprotein. J Comput Aided Mol Des (2013) 0.75
Does transbilayer diffusion have a role in membrane transport of drugs? Drug Discov Today (2012) 0.75
Intracellular drug bioavailability: a new predictor of system dependent drug disposition. Sci Rep (2017) 0.75
Lipid-associated oral delivery: Mechanisms and analysis of oral absorption enhancement. J Control Release (2016) 0.75
Dissecting rapid estrogen signaling with conjugates. Steroids (2012) 0.75
Ability of Mn(2+) to Permeate the Eye and Availability of Manganese-enhanced Magnetic Resonance Imaging for Visual Pathway Imaging via Topical Administration. Chin Med J (Engl) (2016) 0.75
Highly predictive and interpretable models for PAMPA permeability. Bioorg Med Chem (2016) 0.75
Gadolinium-Doped Gallic Acid-Zinc/Aluminium-Layered Double Hydroxide/Gold Theranostic Nanoparticles for a Bimodal Magnetic Resonance Imaging and Drug Delivery System. Nanomaterials (Basel) (2017) 0.75
Exploitation of a newly-identified entry pathway into the malaria parasite-infected erythrocyte to inhibit parasite egress. Sci Rep (2017) 0.75
Role of the OATP Transporter Family and a Benzbromarone-SensitiveEfflux Transporter in the Hepatocellular Disposition of Vincristine. Pharm Res (2017) 0.75
A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res (1995) 12.09
Membrane transporters in drug development. Nat Rev Drug Discov (2010) 8.56
Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem (2002) 6.85
Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell (1994) 6.02
Reconstitution of cell membrane structure in vitro and its transformation into an excitable system. Nature (1962) 5.33
Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res (2005) 4.13
On the mechanism of intestinal absorption of drugs. J Pharmacol Exp Ther (1959) 3.16
Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther (2007) 2.52
MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci (1999) 2.40
Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet (2003) 2.27
Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res (1999) 2.24
Permeability of small nonelectrolytes through lipid bilayer membranes. J Membr Biol (1986) 2.21
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther (2002) 2.21
Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther (1997) 2.17
Monocarboxylic acid permeation through lipid bilayer membranes. J Membr Biol (1984) 2.04
OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos (1999) 2.02
Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nat Protoc (2007) 1.98
Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos (2007) 1.97
Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. J Med Chem (1998) 1.96
The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv (2004) 1.96
Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? Nat Rev Drug Discov (2008) 1.93
Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci (2006) 1.85
A comparison of physiochemical property profiles of development and marketed oral drugs. J Med Chem (2003) 1.81
Permeability, transport, and metabolism of solutes in Caco-2 cell monolayers: a theoretical study. Drug Metab Dispos (2007) 1.72
Pharmaceutical and pharmacological importance of peptide transporters. J Pharm Pharmacol (2008) 1.70
5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm Res (1998) 1.66
In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab Dispos (2007) 1.63
Analysis and update of the human solute carrier (SLC) gene superfamily. Hum Genomics (2009) 1.62
Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics (2001) 1.58
Blood-brain barrier permeation: molecular parameters governing passive diffusion. J Membr Biol (1998) 1.55
Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther (1997) 1.55
Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci (2006) 1.52
Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther (2008) 1.50
Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm Res (2009) 1.46
High throughput artificial membrane permeability assay for blood-brain barrier. Eur J Med Chem (2003) 1.46
The role of transporters in the pharmacokinetics of orally administered drugs. Pharm Res (2009) 1.46
A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J Pharm Sci (2000) 1.45
Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm Res (1997) 1.44
Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem Biophys Res Commun (1998) 1.43
Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur J Pharm Sci (2006) 1.43
Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int J Pharm (2004) 1.41
Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet (2002) 1.41
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. J Med Chem (2001) 1.39
Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm Res (2002) 1.37
The relationship between permeant size and permeability in lipid bilayer membranes. J Membr Biol (1994) 1.35
Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther (2008) 1.34
The solute carrier (SLC) complement of the human genome: phylogenetic classification reveals four major families. FEBS Lett (2008) 1.34
Influence of chain ordering on the selectivity of dipalmitoylphosphatidylcholine bilayer membranes for permeant size and shape. Biophys J (1998) 1.33
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. J Med Chem (2008) 1.32
The role of size and charge for blood-brain barrier permeation of drugs and fatty acids. J Mol Neurosci (2007) 1.31
Diffusion of small non-electrolytes across liposome membranes. Nature (1972) 1.30
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos (2008) 1.29
Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin Drug Metab Toxicol (2009) 1.28
Intestinal permeability and its relevance for absorption and elimination. Xenobiotica (2007) 1.26
Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm Res (2006) 1.26
Current industrial practices of assessing permeability and P-glycoprotein interaction. AAPS J (2006) 1.23
Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu Rev Pharmacol Toxicol (2005) 1.23
Profiling drug-like properties in discovery research. Curr Opin Chem Biol (2003) 1.22
Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors. J Pharm Sci (2001) 1.21
A new model of weak acid permeation through membranes revisited: does Overton still rule? Biophys J (2006) 1.21
Bioavailability and pharmacokinetics of cimetidine. Eur J Clin Pharmacol (1979) 1.21
Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. J Med Chem (1998) 1.21
Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. Clin Pharmacol Ther (2007) 1.20
Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weight. Eur J Pharm Sci (1998) 1.19
Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J Clin Pharmacol (2009) 1.18
Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharm Res (2007) 1.18
Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics. Clin Pharmacol Ther (2005) 1.17
Isolation of a family of organic anion transporters from human liver and kidney. Biochem Biophys Res Commun (2001) 1.17
Human intestinal permeability. J Pharm Sci (1998) 1.17
Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories. Eur J Pharm Sci (2008) 1.16
Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res (2003) 1.14
pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions. Pharm Res (2003) 1.13
ADME evaluation in drug discovery. 5. Correlation of Caco-2 permeation with simple molecular properties. J Chem Inf Comput Sci (2004) 1.13
IAM chromatography: an in vitro screen for predicting drug membrane permeability. J Med Chem (1995) 1.10
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). J Med Chem (2008) 1.10
PAMPA--critical factors for better predictions of absorption. J Pharm Sci (2007) 1.10
Transport of drugs by proton-coupled peptide transporters: pearls and pitfalls. Expert Opin Drug Metab Toxicol (2009) 1.10
Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. Pharm Res (2006) 1.09
Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation. Br J Pharmacol (1996) 1.08
Using the Golden Triangle to optimize clearance and oral absorption. Bioorg Med Chem Lett (2009) 1.07
An integrated model for determining causes of poor oral drug absorption. Pharm Res (1999) 1.07
Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers. Clin Pharmacol Ther (1998) 1.07
Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res (2001) 1.07
Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol Pharmacol (2005) 1.07
Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-transporting polypeptide 1B1 (SLCO1B1). Drug Metab Dispos (2008) 1.06
Caco-2 permeability of weakly basic drugs predicted with the double-sink PAMPA pKa(flux) method. Eur J Pharm Sci (2005) 1.06
The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res (2001) 1.05
Membrane transporters. Eur J Pharm Sci (2000) 1.05
Investigation of the inhibitory effects of various drugs on the hepatic uptake of fexofenadine in humans. Drug Metab Dispos (2008) 1.04
Variability in Caco-2 and MDCK cell-based intestinal permeability assays. J Pharm Sci (2008) 1.04
Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1. J Med Chem (2005) 1.04
A comparative study of artificial membrane permeability assay for high throughput profiling of drug absorption potential. Eur J Med Chem (2002) 1.03
Intestinal drug absorption and metabolism in cell cultures: Caco-2 and beyond. Pharm Res (1997) 1.03
Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport. Mol Pharm (2005) 1.03
The effect of L-leucine on the absorption of levodopa, studied by regional jejunal perfusion in man. Br J Clin Pharmacol (1993) 1.03
Substituent contributions to the transport of substituted p-toluic acids across lipid bilayer membranes. J Pharm Sci (1994) 1.02
Taxol transport by human intestinal epithelial Caco-2 cells. Drug Metab Dispos (1998) 1.02
The rise of PAMPA. Expert Opin Drug Metab Toxicol (2005) 1.02
PAMPA--a drug absorption in vitro model 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur J Pharm Sci (2004) 1.02
Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm Res (2003) 1.01
Fluorine in medicinal chemistry. Chembiochem (2004) 3.25
Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nat Protoc (2007) 1.98
Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos (2007) 1.97
The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Discov (2010) 1.94
A new principle for tight junction modulation based on occludin peptides. Mol Pharmacol (2003) 1.88
Predicting plasma protein binding of drugs: a new approach. Biochem Pharmacol (2002) 1.85
Development of a virtual screening method for identification of "frequent hitters" in compound libraries. J Med Chem (2002) 1.63
The N terminus of monoamine transporters is a lever required for the action of amphetamines. J Biol Chem (2010) 1.58
Alkylamides from Echinacea are a new class of cannabinomimetics. Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects. J Biol Chem (2006) 1.54
Predicting and tuning physicochemical properties in lead optimization: amine basicities. ChemMedChem (2007) 1.48
Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm Res (2009) 1.46
Spirocyclic oxetanes: synthesis and properties. Angew Chem Int Ed Engl (2008) 1.44
Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur J Pharm Sci (2006) 1.43
Pharmacological promiscuity: dependence on compound properties and target specificity in a set of recent Roche compounds. ChemMedChem (2009) 1.42
Halogenation of drugs enhances membrane binding and permeation. Chembiochem (2004) 1.40
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. J Med Chem (2008) 1.32
Diazepam-bound GABAA receptor models identify new benzodiazepine binding-site ligands. Nat Chem Biol (2012) 1.31
Oxetanes as promising modules in drug discovery. Angew Chem Int Ed Engl (2006) 1.31
Oxetanes in drug discovery: structural and synthetic insights. J Med Chem (2010) 1.24
The high-affinity binding site for tricyclic antidepressants resides in the outer vestibule of the serotonin transporter. Mol Pharmacol (2010) 1.21
Modeling promiscuity based on in vitro safety pharmacology profiling data. ChemMedChem (2007) 1.21
Absorption classification of oral drugs based on molecular surface properties. J Med Chem (2003) 1.19
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem (2012) 1.18
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem (2003) 1.18
Hybrid inhibitors of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): design, synthesis, and superior antitumor activity of novel wortmannin-rapamycin conjugates. J Med Chem (2010) 1.17
Classification analysis of P-glycoprotein substrate specificity. J Drug Target (2003) 1.17
Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories. Eur J Pharm Sci (2008) 1.16
Transport of nanoparticles across an in vitro model of the human intestinal follicle associated epithelium. Eur J Pharm Sci (2005) 1.16
Mutational analysis of the high-affinity zinc binding site validates a refined human dopamine transporter homology model. PLoS Comput Biol (2013) 1.14
pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions. Pharm Res (2003) 1.13
In situ imaging of electrochemically induced oxygen spillover on Pt/YSZ catalysts. Angew Chem Int Ed Engl (2006) 1.13
A global drug inhibition pattern for the human ATP-binding cassette transporter breast cancer resistance protein (ABCG2). J Pharmacol Exp Ther (2007) 1.12
PAMPA--critical factors for better predictions of absorption. J Pharm Sci (2007) 1.10
Molecular design of chitosan gene delivery systems with an optimized balance between polyplex stability and polyplex unpacking. Biomaterials (2009) 1.10
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). J Med Chem (2008) 1.10
P-glycoprotein substrate binding domains are located at the transmembrane domain/transmembrane domain interfaces: a combined photoaffinity labeling-protein homology modeling approach. Mol Pharmacol (2004) 1.09
Experimental and computational screening models for prediction of aqueous drug solubility. Pharm Res (2002) 1.09
High throughput solubility measurement in drug discovery and development. Adv Drug Deliv Rev (2007) 1.06
Caco-2 permeability of weakly basic drugs predicted with the double-sink PAMPA pKa(flux) method. Eur J Pharm Sci (2005) 1.06
Exhaustive sampling of docking poses reveals binding hypotheses for propafenone type inhibitors of P-glycoprotein. PLoS Comput Biol (2011) 1.06
Scientific competency questions as the basis for semantically enriched open pharmacological space development. Drug Discov Today (2013) 1.04
Structure-activity relationships, ligand efficiency, and lipophilic efficiency profiles of benzophenone-type inhibitors of the multidrug transporter P-glycoprotein. J Med Chem (2012) 1.03
Inhibitory activity of prostaglandin E2 production by the synthetic 2'-hydroxychalcone analogues: Synthesis and SAR study. Bioorg Med Chem Lett (2009) 1.03
Endogenous gene and protein expression of drug-transporting proteins in cell lines routinely used in drug discovery programs. Drug Metab Dispos (2009) 1.02
Dissolution rate and apparent solubility of poorly soluble drugs in biorelevant dissolution media. Mol Pharm (2010) 1.02
PAMPA--a drug absorption in vitro model 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur J Pharm Sci (2004) 1.02
In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions. Pharm Res (2011) 1.01
Computational toxicology in drug development. Drug Discov Today (2008) 1.01
ICL670A: preclinical profile. Adv Exp Med Biol (2002) 1.01
Design, data analysis, and simulation of in vitro drug transport kinetic experiments using a mechanistic in vitro model. Drug Metab Dispos (2008) 0.99
Fluorine interactions at the thrombin active site: protein backbone fragments H-C(alpha)-C=O comprise a favorable C-F environment and interactions of C-F with electrophiles. Chembiochem (2004) 0.99
Amphetamine actions at the serotonin transporter rely on the availability of phosphatidylinositol-4,5-bisphosphate. Proc Natl Acad Sci U S A (2013) 0.99
Pharmaceutical profiling in drug discovery. Drug Discov Today (2003) 0.98
Annotating Human P-Glycoprotein Bioassay Data. Mol Inform (2012) 0.98
Accuracy of calculated pH-dependent aqueous drug solubility. Eur J Pharm Sci (2004) 0.98
PAMPA--a drug absorption in vitro model. 5. Unstirred water layer in iso-pH mapping assays and pKa(flux)--optimized design (pOD-PAMPA). Eur J Pharm Sci (2003) 0.97
Insights for predicting blood-brain barrier penetration of CNS targeted molecules using QSPR approaches. J Chem Inf Model (2010) 0.97
In vitro trans-monolayer permeability calculations: often forgotten assumptions. Drug Discov Today (2003) 0.96
Molecular dissection of dual pseudosymmetric solute translocation pathways in human P-glycoprotein. Mol Pharmacol (2010) 0.95
β-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease. J Med Chem (2013) 0.95
Identification of 3-sulfonylindazole derivatives as potent and selective 5-HT(6) antagonists. Bioorg Med Chem (2010) 0.95
Rapid measurement of intracellular unbound drug concentrations. Mol Pharm (2013) 0.95
pH-Dependent passive and active transport of acidic drugs across Caco-2 cell monolayers. Eur J Pharm Sci (2005) 0.94
Predominant contribution of organic anion transporting polypeptide OATP-B (OATP2B1) to apical uptake of estrone-3-sulfate by human intestinal Caco-2 cells. Drug Metab Dispos (2006) 0.93
A fluorine scan of the phenylamidinium needle of tricyclic thrombin inhibitors: effects of fluorine substitution on pKa and binding affinity and evidence for intermolecular C-F...CN interactions. Org Biomol Chem (2004) 0.93
Characterization of antigen and bacterial transport in the follicle-associated epithelium of human ileum. Lab Invest (2006) 0.92
5-Alkylated thiazolidinones as follicle-stimulating hormone (FSH) receptor agonists. Bioorg Med Chem (2006) 0.92
pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery. Mol Pharm (2012) 0.92
Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci (2013) 0.92
Combined application of parallel artificial membrane permeability assay and Caco-2 permeability assays in drug discovery. J Pharm Sci (2004) 0.92
Enhancement of drug absorption by noncharged detergents through membrane and P-glycoprotein binding. Expert Opin Drug Metab Toxicol (2006) 0.91
Multispecificity of drug transporters: probing inhibitor selectivity for the human drug efflux transporters ABCB1 and ABCG2. ChemMedChem (2007) 0.91
A vascular cause of painful lumbar transverse syndrome. J Spinal Cord Med (2009) 0.90
Solubility-excipient classification gradient maps. Pharm Res (2007) 0.90
Yersinia pseudotuberculosis induces transcytosis of nanoparticles across human intestinal villus epithelium via invasin-dependent macropinocytosis. Lab Invest (2008) 0.90
Similarity-based SIBAR descriptors for classification of chemically diverse hERG blockers. Mol Divers (2009) 0.90
Lead identification for modulators of multidrug resistance based on in silico screening with a pharmacophoric feature model. Arch Pharm (Weinheim) (2004) 0.90
Modulation of GABAA-receptors by honokiol and derivatives: subtype selectivity and structure-activity relationship. J Med Chem (2011) 0.89
Prediction of the oral absorption of low-permeability drugs using small intestine-like 2/4/A1 cell monolayers. Pharm Res (2003) 0.89
Synthesis of azaspirocycles and their evaluation in drug discovery. Angew Chem Int Ed Engl (2010) 0.89
In vitro solubility assays in drug discovery. Curr Drug Metab (2008) 0.89
Extending pKa prediction accuracy: high-throughput pKa measurements to understand pKa modulation of new chemical series. Eur J Med Chem (2010) 0.89
Metabolic soft spot identification and compound optimization in early discovery phases using MetaSite and LC-MS/MS validation. J Med Chem (2009) 0.89
Random mutagenesis of the prokaryotic peptide transporter YdgR identifies potential periplasmic gating residues. J Biol Chem (2011) 0.89
Applications of epithelial cell culture in studies of drug transport. Methods Mol Biol (2002) 0.88
Molecular descriptors influencing melting point and their role in classification of solid drugs. J Chem Inf Comput Sci (2003) 0.88
Medicinal chemistry design principles for liver targeting through OATP transporters. Curr Top Med Chem (2013) 0.88
P-glycoprotein deficient mouse in situ blood-brain barrier permeability and its prediction using an in combo PAMPA model. Eur J Pharm Sci (2009) 0.88